← Back to Search

Liquid Biopsy

Liquid Biopsy for Lung Cancer

N/A
Recruiting
Led By Dan Raz, MD
Research Sponsored by City of Hope Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing how well cell-free DNA liquid biopsy works in screening high-risk patients for lung cancer.

Who is the study for?
This trial is for English-speaking individuals aged 50-80 who are at high risk for lung cancer due to a smoking history of 20 or more pack-years and, if they've quit, it was within the last 15 years. They must consent to screening with liquid biopsy or CT scan and have insurance covering LDCT at specified centers. Excluded are those with any recent cancer diagnosis (except non-melanoma skin cancer) or symptoms of lung cancer.
What is being tested?
The study is testing the practicality of using cell-free DNA liquid biopsies for early detection of lung cancer in high-risk patients compared to low dose CT scans. It aims to see if positive results from liquid biopsies encourage patients to follow up with CT scans, potentially increasing early detection rates.
What are the potential side effects?
There may be minimal side effects associated with providing a blood sample for the liquid biopsy. The low dose CT scan involves exposure to a small amount of radiation but generally has few immediate side effects.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Screening preference
Secondary study objectives
Participants who follow-through on screening 1
Participants who follow-through on screening 2
Participants who follow-through on screening 3
+8 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Cohort B (LDCT, optional liquid biopsy)Experimental Treatment3 Interventions
Participants undergo low dose CT with optional liquid biopsy on the same day as LDCT.
Group II: Cohort A (liquid biopsy, optional LDCT)Experimental Treatment3 Interventions
Participants undergo collection of blood sample (liquid biopsy), with option to undergo LDCT if liquid biopsy results are positive.

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,958 Previous Clinical Trials
41,112,472 Total Patients Enrolled
City of Hope Medical CenterLead Sponsor
605 Previous Clinical Trials
1,923,497 Total Patients Enrolled
Dan Raz, MDPrincipal InvestigatorCity of Hope Medical Center
1 Previous Clinical Trials
382 Total Patients Enrolled
Dan RazPrincipal InvestigatorCity of Hope Medical Center
3 Previous Clinical Trials
502 Total Patients Enrolled
~32 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top